Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This phase 2 trial is testing the targeted drug brigatinib in 118 people with ALK-positive non-small cell lung cancer that has spread or cannot be surgically removed. The main goal is to see how long the cancer stays under control before it progresses. Researchers are also studyi…

This study tests whether adding immunotherapy drugs (durvalumab and tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults with this rare liver cancer will …

This study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has a specific FGFR2 gene change. The goal is to see if the combination shrinks tumors. Participants receive bo…

This study tests whether combining the targeted drug trastuzumab-deruxtecan with other treatments before surgery is safe and feasible for people with HER2-positive stomach or esophagus cancer that has not spread. About 36 adults will receive the drug combinations before their pla…

This study tests a drug called bemarituzumab combined with different chemotherapies in 126 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). Participants have already tried at least one prior chemotherapy. The goal is to see if…

This study tests a three-drug combination (chemotherapy plus two targeted therapies) as a first treatment for people with a specific type of bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors and improves surviv…

This study tests a new combination of three drugs (rituximab, polatuzumab vedotin, and glofitamab) for people over 60 with aggressive B-cell lymphoma who cannot tolerate standard full-dose chemotherapy. The goal is to see if this milder treatment can control the disease and impro…

This study looks at whether a new combination of drugs (ramucirumab plus FOLFIRI) can help people with advanced stomach or gastroesophageal junction cancer live longer. It is for patients whose cancer got worse after one round of chemotherapy. The trial compares this new combo to…